A retrospective study was performed on a selected cohort of 40 liver transplant recipients derived from the previous prospective follow-up of 162 liver transplant patients. The criterion for selection of this cohort was the presence of human cytomegalovirus (HCMV) DNAemia after transplantation, as determined by qualitative polymerase chain reaction (PCR). These 40 patients were followed longitudinally by quantitative PCR and by the new recombinant antigen-based AxSYM immunoassay for IgM to HCMV. The detection of IgM to CMV after transplantation was significantly associated with the development of HCMV disease in patients who had evidence of active HCMV replication in the blood by PCR ( ). On the basis P p .01 of multivariate logistic regression analyses, the maximum titer of IgM detected after transplantation was a risk factor that was independent of augmented methylprednisolone and donor seropositivity. However, in multivariate analyses, elevated virus load continued to be the predominant risk factor for progression to HCMV disease.
A retrospective study was performed on a selected cohort of 40 liver transplant recipients derived from the previous prospective follow-up of 162 liver transplant patients. The criterion for selection of this cohort was the presence of human cytomegalovirus (HCMV) DNAemia after transplantation, as determined by qualitative polymerase chain reaction (PCR). These 40 patients were followed longitudinally by quantitative PCR and by the new recombinant antigen-based AxSYM immunoassay for IgM to HCMV. The detection of IgM to CMV after transplantation was significantly associated with the development of HCMV disease in patients who had evidence of active HCMV replication in the blood by PCR ( ). On the basis P p .01 of multivariate logistic regression analyses, the maximum titer of IgM detected after transplantation was a risk factor that was independent of augmented methylprednisolone and donor seropositivity. However, in multivariate analyses, elevated virus load continued to be the predominant risk factor for progression to HCMV disease.
Human cytomegalovirus (HCMV) continues to be a major cause of morbidity and mortality after solid organ transplantation and is the most common cause of infection after liver transplantation, with an incidence of 20%-60% [1] [2] [3] . Approximately 50% of infected patients will progress to HCMV disease. Risk factors for disease include receipt of large doses of immunosuppressive therapy, transplantation of an organ from an HCMV-seropositive donor into an HCMV-seronegative recipient, and HCMV viremia [4] [5] [6] [7] . Clinical manifestations of HCMV disease range from persistent fever and mononucleosislike syndrome to severe invasive organ disease, such as HCMV hepatitis, gastrointestinal disease, and pneumonitis [8] . The current availability of antiviral agents that are able to control HCMV replication has led to the desire for the early identification of active HCMV replication and the use of preemptive therapeutic intervention to reduce the number of patients who will progress to HCMV disease [9] [10] [11] [12] [13] [14] . The results of many studies have confirmed that the rapid detection of HCMV DNAemia in plasma, serum, and whole blood can provide prognostic information for liver transplant recipients [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] .
In contrast to the prognostic information obtained by detecting HCMV viremia, the diagnostic utility of monitoring transplant patients for the presence of IgM antibody to HCMV after transplantation has been questioned by several studies, because of the reported insensitivity of serological tests relative to antigen detection methods and the apparent late appearance of HCMV-specific IgM after infection [2, 20, [25] [26] [27] [28] [29] [30] . The apparent lack of utility for monitoring transplant recipients after transplantation by conventional serological methods may be due to the insensitive viral antigen-based HCMV-specific IgM assays. We have previously shown that a cocktail of purified recombinant protein antigens containing portions of pUL32 (pp150), pUL44 (pp52), pUL83 (pp65), and pUL80a (pp38) was both necessary and sufficient to replace the crude viral antigen preparation in a microtiter ELISA for the detection of HCMV-specific IgM [31, 32] . This recombinant antigen microtiter ELISA was more sensitive than a viral antigen microtiter ELISA and was able to detect the presence of HCMV-specific IgM in response to HCMV disease, before the detection of viral proteins by the pp65 antigenemia assay in some patients [31] . We recently described the development of the automated AxSYM assay, which uses these recombinant antigens for the detection of HCMV-specific IgM [33] . In this study, we used the AxSYM assay to measure HCMV-specific IgM levels after liver transplantation and correlated appearance and quantity of IgM with virus load, donor and recipient serostatus, and administration of augmented immunosuppressive medication, to ascertain the diagnostic utility of this new immunoassay in monitoring liver transplant recipients.
Materials and Methods

Study population and detection of CMV DNA by polymerase chain reaction (PCR).
A total of 162 patients with 1433 surveillance blood samples were followed prospectively from 1992 through 1996 for HCMV infection by use of a qualitative DNA PCR assay on whole blood. Forty-seven patients were found to be positive by this assay, and samples were then quantitated by a quantitative-competitive PCR assay. Details of these patients and the immunosuppressive regimen used to manage them have been reported [22] . The qualitative and quantitative-competitive PCR assays used in this study have been described [34] [35] [36] [37] . If histological evidence of moderate to severe rejection episodes was present, patients were treated with methylprednisolone (1 g daily intravenously) for 3 days, which was repeated if subsequent episodes occurred.
Clinical diagnosis. HCMV infection was diagnosed by PCR for HCMV DNA, culture, detection of early antigen fluorescent foci (shell vial), or histology. HCMV disease was determined, on the basis of the criteria of the International CMV Workshop [38] , as typical features of HCMV infection resulting in associated symptoms within 2 weeks of the detection of virus. Three manifestations were used: pyrexia with viremia (fever у38ЊC for у48 h in the absence of rejection or bacterial or fungal infection associated with viremia); hepatitis (alteration in liver function test results [alanine aminotransferase value у2 times the upper limit of normal] in the absence of bacterial or fungal infection or in association with HCMV detection in liver biopsy specimens by virological and/or histological techniques); or pneumonitis (symptoms of hypoxia and/or characteristic interstitial chest radiograph pattern, lack of response to antibiotics, and HCMV infection detected in bronchoalveolar lavage fluid). The median onset of HCMV disease was 43 days (range, 25-126 days).
Serological analysis. Serum samples from donors and recipients were tested for IgG antibodies to HCMV and herpes simplex virus antibodies by EIA (Biokit, Barcelona, Spain).
Assay for HCMV-specific IgM. In patients with detectable HCMV DNAemia, longitudinal serum samples were analyzed for the presence of IgM antibodies to HCMV by the AxSYM assay (Abbott), as described elsewhere [33] . A total of 394 serum samples from 40 patients were tested. The remaining 7 patients from the original cohort had a median of 1 serum sample available for analysis and thus were excluded from the IgM analyses.
Statistical methods. The significance of differences between maximum IgM levels in each group was assessed by the MannWhitney U test. Univariate analysis was used to examine factors of interest (virus load, donor and recipient serostatus, and IgM titer) by use of Fisher's exact test, with continuity adjustment as required, or by the Mann-Whitney U test; significant relationships were quantified by logistic regression analysis. The results were used to generate an equation to determine the probability of being symptomatic at any given virus load or IgM titer in the presence or absence of methylprednisolone in an independent manner, regardless of the timing of HCMV infection. In these analyses, ratios quoted refer to each 0.25-log increase in virus load and each 1-g increase in methylprednisolone.
Results
A retrospective study was done on a selected cohort of 40 liver transplant recipients derived from the previous prospective follow-up of 162 liver transplant patients. The criteria for selection was the presence of DNAemia after transplantation, as detected by qualitative PCR. These 40 patients were followed longitudinally by quantitative PCR and by the AxSYM assay for HCMV-specific IgM. Nineteen patients in this cohort had HCMV disease and were treated with ganciclovir. There was a significant correlation between detection of IgM antibodies to HCMV by the AxSYM assay and HCMV disease (table 1) . Although all patients were positive for DNAemia by qualitative PCR, only 29 of 40 were positive for HCMV-specific IgM.
The relative timing of detection of DNAemia by qualitative PCR and detection of HCMV-specific IgM by the AxSYM assay was examined longitudinally in all 40 liver transplant recipients (table 2) . Among 19 patients with HCMV disease, DNAemia was detected before HCMV-specific IgM in 8 (42%). In 1 patient (5%), no HCMV-specific IgM was detected, although this patient had HCMV hepatitis. Among the 10 remaining patients with HCMV disease (53%), AxSYM detected HCMV-specific IgM before the detection of DNAemia in 2 patients (11%), the detection of DNAemia and HCMV-specific IgM occurred at about the same time in 7 patients (37%), and the timing was unknown because of the unavailability of serial specimens for testing by AxSYM in 1 patient (5%). Twenty-one patients had asymptomatic HCMV infection. DNAemia was detected before HCMVspecific IgM in 2 patients (10%), HCMV-specific IgM was detected in 2 patients before DNAemia (10%), detection of DNAemia and HCMV-specific IgM occurred at about the same time in 3 patients (14%), and the timing of IgM appearance was unknown in 4 patients (19%). There were 10 asymptomatic patients (47%), in whom no HCMV-specific IgM was detected. Among 2 patients with HCMV disease, detection of HCMVspecific IgM preceded the detection of DNAemia; thus, the sensitivity, specificity, negative predictive value, and positive predictive value of IgM positivity for HCMV disease were 94.7%, 47.6%, 62%, and 91%, respectively.
The timing of DNAemia and HCMV-specific IgM, according to HCMV-specific IgG serostatus of donor-recipient pairs before transplantation, is shown in table 3. Among HCMV IgGseropositive recipients of transplants from HCMV IgGseropositive donors ( ), DNAemia was detected before n p 14 HCMV-specific IgM in 3 patients (21%), detection of DNAemia and HCMV-specific IgM occurred at about the same time in 5 patients (36%), no HCMV-specific IgM was detected in 3 patients (21%), and the timing of IgM appearance was unknown in 3 patients (21%). Among HCMV IgG-seronegative recipients of transplants from HCMV IgG-seropositive donors ( ), n p 14 DNAemia was detected before HCMV-specific IgM in 7 patients (50%), detection of DNAemia and HCMV-specific IgM occurred at about the same time in 3 patients (22%), HCMV-specific IgM was detected before DNAemia in 1 patient (7%), and no HCMVspecific IgM was detected in 3 patients (21%). In HCMV IgG-seropositive recipients of transplants from HCMV IgGseronegative donors ( ), detection of DNAemia and n p 12 HCMV-specific IgM occurred at about the same time in 2 patients (17%), HCMV-specific IgM was detected before DNAemia in 3 patients (25%), no HCMV-specific IgM was detected in 5 patients (42%), and the timing of IgM appearance was unknown in 2 patients (16%). As shown in table 3, among all 10 patients in whom DNAemia preceded HCMV-specific IgM positivity, the donor was HCMV IgG seropositive (recipient also HCMV IgG seropositive, ; recipient HCMV IgG seronegative, ). n p 3 n p 7 In contrast, 3 of 4 patients who had HCMV DNA detected after HCMV-specific IgM received an organ from an HCMV IgG-seronegative donor.
The timing between first PCR-positive and first HCMV-spe- NOTE. In bivariate analysis, "maximum titer" and entry immediately below it were analyzed concurrently. CI, confidence interval; OR, odds ratio.
cific IgM-positive results and the onset of symptoms in the 19 transplant recipients who progressed to HCMV disease is shown in figure 1 . There were no significant differences between the median time between either the detection of DNAemia by PCR or the first detection of HCMV-specific IgM and the onset of symptoms. To further investigate the relationship between the quantitative appearance of virus and the quantitative modulations in IgM, we compared the peak virus load (log 10 genomes/mL of blood) and peak IgM titer (in arbitrary units) detected in patients with HCMV disease. As shown in figure  2 , peak IgM levels were detected at a median of 24 days after symptoms occurred, whereas peak virus load was usually detected simultaneously with clinically overt disease ( ). P ! .01 There was a significant correlation between peak IgM titer and peak virus load ( , Spearman's test; data not shown). P p .02 The interrelationship between presence of disease and maximum IgM titer in the context of other risk factors for HCMV disease was investigated by use of univariate, bivariate, and multivariate logistic regression analyses (table 4) . Maximum IgM titer was significantly associated with an increased risk of HCMV disease in patients with detectable DNA in whole blood (odds ratio, 1.76;
). In bivariate models, the maximum P p .02 titer of IgM was a risk factor for disease, which was independent of methylprednisolone use and donor and recipient serostatus (table 4) . However, when the maximum titer of IgM and the maximum virus load were incorporated into the same model, virus load was significantly associated with increased disease risk, whereas the significance of maximum IgM titer was nullified. Multivariate analyses that incorporated maximum IgM titer, maximum virus load, and donor and recipient serostatus showed that only virus load remained a significant risk factor for disease. On the basis of logistic regression analysis, we constructed disease-probability curves to investigate the influence of total methylprednisolone dose on the IgM titer-disease curve in the multivariate setting ( figure 3 ). The influence of increasing doses of methylprednisolone was to shift the probability-of-disease curve to lower IgM titers; that is, a progressively lower threshold level of IgM antibody was required at high doses of augmented methylprednisolone to achieve the same probability of disease.
Discussion
We evaluated the utility of the new recombinant antigenbased AxSYM assay for HCMV-specific IgM [33] in a cohort of liver transplant patients who experienced DNAemia after transplantation. Our data show that the detection of HCMVspecific IgM after transplantation was significantly associated with the development of HCMV disease in patients who had evidence of active HCMV replication in the blood by PCR Figure 3 . Effects of increasing total dose of methylprednisolone (0, 3, 6, 9, and 12 g) on IgM titer-probability-of-disease curve, computed from multiple logistic regression analysis.
(table 1). Furthermore, even in patients receiving large doses of augmented immunosuppressive medication, HCMV-specific IgM was detectable by the AxSYM assay and could theoretically enable initiation of preemptive therapeutic regimens at an early stage, before the development of clinically overt HCMV disease. Indeed, for the patients investigated here, a preemptive therapeutic approach based on HCMV-specific IgM detection after transplantation would have resulted in the treatment of 29 patients, of whom 18 would have gone on to develop HCMV disease. One patient, who progressed to HCMV disease but did not produce detectable HCMV-specific IgM, would have been missed by this approach. In contrast, preemptive therapy initiated on the basis of 2 consecutive PCR-positive results would have resulted in the treatment of 36 of the patients, 19 of whom progressed to HCMV disease.
Longitudinal analysis of this patient cohort indicated that analyzing liver transplant recipients by both PCR and the AxSYM assay may produce complementary results, since some patients who develop HCMV disease are sometimes identified earlier by HCMV-specific IgM serology than by PCR (table 2). The 2 patients who progressed to HCMV disease who had been identified earlier by the AxSYM assay before presentation of symptoms had organ involvement (gastrointestinal or lung). One of the limitations of detection of HCMV infection in the blood by PCR is that use of this sample type to detect infection assumes that events in the peripheral blood parallel those occurring in target organs. Although this is frequently the case, the immune system can detect organ involvement with HCMV and produce antibodies in response to infection that can readily be measured in the peripheral blood regardless of the location of the site of infection. An HCMV-primed immune system appears to be important for the early detection of infection by the AxSYM assay for HCMV-specific IgM, because 3 of the 4 recipients identified earlier by the AxSYM assay were seropositive for HCMV IgG before transplantation (table 3) . Our data are in contrast to those of a previous liver transplant study [20] , in which the detection of HCMV-specific IgM antibodies by a viral antigen-based CMV IgM test occurred late in response to HCMV infection and never preceded the onset of HCMV disease. The lack of utility of monitoring liver transplant recipients by HCMV-specific IgM serology in the former study may, in part, be explained by the insensitivity of the viral antigen HCMV-specific IgM test used.
The risk factors for disease identified here-elevated virus load, administration of augmented methylprednisolone, and donor seropositivity-are consistent with those identified in previous studies from our group and others [2] [3] [4] [5] [6] [7] 22] . By use of multivariate logistic regression analyses, we showed that the maximum titer of IgM detected after transplantation was a risk factor that was independent of augmented methylprednisolone and donor seropositivity. However, these analyses also revealed that the maximum titer of IgM was not independent of elevated virus load. Thus, in multivariate analyses, elevated virus load continued to be the predominant risk factor for disease. To further investigate the interrelationships between maximum IgM titer, disease, and administration of augmented immunosuppressive medication, we constructed disease-probability curves for different doses of augmented immunosuppressive medication, which revealed that methylprednisolone acted to reduce the maximum titer of IgM required to produce the same probability of disease. These results are reminiscent of data previously obtained by our group that related the effects of methylprednisolone on virus load and probability of disease [22] . Therefore, it is likely that the shift in maximum IgM titer observed in the presence of methylprednisolone predominantly reflects the lower virus load that is required to be reached to produce the same probability of disease. Consistent with this possibility is the significant correlation observed between maximum virus load after transplantation and maximum IgM titer ( ). In addition, the immunosup-P p .02 pressive action of methylprednisolone may reduce the capacity of the immune system to mount an IgM response.
In conclusion, this longitudinal study shows the diagnostic utility of a new-generation recombinant antigen-based IgM assay and has allowed for the relationship between IgM titer and virus load to be investigated. The AxSYM assay is a sensitive test for the detection of HCMV-specific IgM. This assay could be used in conjunction with PCR for the clinical management of HCMV infection and disease after liver transplantation.
